Venous leg ulcers (VLUs) are wounds affecting the lower part of the legs linked to deep vein thrombosis (DVT) and varicose veins, in turn creating 'venous hypertension' (associated with a build-up of blood, fluids and proteins in the affected parts). The skin breaks down and frequently, the wounds become infected, oozing, and offensive smelling. Patients suffer considerable pain and distress for prolonged periods, often for many months or years, and become increasingly socially isolated. Furthermore, globally, VLUs absorb significant financial and nursing resources. Graduated compression therapy using tensioned, elasticated bandages is the accepted 'gold standard' treatment for VLUs. Success relies heavily on nurses achieving the exact prescribed compression profile; however, research shows that nurses are significantly incorrect in \>70% of cases (and so seriously wrong as to cause more harm in \>10% of cases). Over-tightening remains the most common problem causing more pain, additional skin damage, and non-compliance with treatment. The inability to achieve accurate and reproducible graduated compression with bandages means ulcers do not heal, potentially become far worse, and patients continue to suffer. Health Services' costs spiral as patients have to be treated for much longer, often years. Improvements in the treatment of VLUs will increase patient wellbeing and outcomes, un-burden nursing services and reduce healthcare systems' expenditure on this costly, chronic condition. To address this challenge, VeinSense Limited are developing a novel medical device to help nurses achieve accurate and reproducible graduated compression profiles 'first time, every time', irrespective of bandage-type used, circumference or shape of limb, or nurse experience. 'VeinSensor' is an optical-based, multi-point pressure sensor strip (placed on the patients' leg under bandaging being applied), connected to a small electronics-processing-unit that displays in real-time onto a mobile/tablet/laptop, the graduated compression levels being applied. The concept has been proven using basic, bench-top, multi-piece prototypes, with significant interest shown from various VLU nursing groups. This project will build upon this early achievement to design and develop prototypes into a low-cost, single piece, mass-producible design, and undertake 'healthy volunteer' testing to achieve initial technology validation. Project outputs will inform next stages of R&D (commercial prototyping, randomised clinical trials) prior to commercial launch. Benefits include: (1) improved patient outcomes for VLU healing rates, quality of life, and treatment compliance, positively affecting all VLU sufferers of which there are \>20m globally, and; (2) significant NHS/healthcare systems' cost-savings (VLUs currently cost £2.2bn/year overall in the UK (and \>$20bn/year in the USA).